These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 846517)

  • 1. Use of levamisole in Hodgkin's disease.
    Berényi E; Sonkoly I; Kávai M; Szabolcsi M; Szegedi G
    N Engl J Med; 1977 Apr; 296(16):941. PubMed ID: 846517
    [No Abstract]   [Full Text] [Related]  

  • 2. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levamisole in the treatment of Hodgkin's disease.
    Berényi E; Kávai M; Szabolcsi M; Szegedi G
    Acta Med Acad Sci Hung; 1979; 36(2):177-85. PubMed ID: 317549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monocyte chemotaxis and effect of levamisole in Hodgkin's disease.
    Lukács K; Frendl G; Berényi E; Kávai M; Szabó G; Szegedi G
    Acta Med Acad Sci Hung; 1980; 37(2):145-50. PubMed ID: 7457021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease.
    Ramot B; Biniaminov M; Shoham C; Rosenthal E
    N Engl J Med; 1976 Apr; 294(15):809-11. PubMed ID: 1082545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: In-vitro resotration by levamisole of thymus-derived lymphocyte function in Hodgkin's disease.
    Biniaminov M; Ramot B
    Lancet; 1975 Feb; 1(7904):464. PubMed ID: 48661
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of advanced Hodgkin's disease in remission.
    Klener P; Hausner P; Donner L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):213-7. PubMed ID: 6179821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of levamisole, thymic humoral factor and indomethacin on e-rosette formation of lymphocytes in Hodgkin's disease.
    Ramot B; Rosenthal E; Biniaminov M; Ben-Bassat I
    Isr J Med Sci; 1981 Apr; 17(4):232-5. PubMed ID: 7195385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levamisole].
    Esposito G; De Maddi F
    Pediatria (Napoli); 1980 Jun; 88(2):295-301. PubMed ID: 7017586
    [No Abstract]   [Full Text] [Related]  

  • 10. Ferritin on the surface of lymphocytes in Hodgkin's disease patients. A possible blocking substance removed by levamisole.
    Moroz C; Lahat N; Biniaminov M; Ramot B
    Clin Exp Immunol; 1977 Jul; 29(1):30-5. PubMed ID: 891036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a thymic factor on the concentration of a factor VIII inhibitor in a patient with treated Hodgkin's disease.
    Richard C; Sedano C; Cuadrado MA; Iriondo A; Bello C; Gandarillas MA; Zubizarreta A
    Thromb Haemost; 1986 Apr; 55(2):299-300. PubMed ID: 3087005
    [No Abstract]   [Full Text] [Related]  

  • 12. Symptom relief with levamisole in stage IV Hodgkin's disease.
    Phillips RH; Retsas S; Newton KA
    Br Med J; 1977 Jun; 1(6074):1447-8. PubMed ID: 861683
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro reversal of cellular unresponsiveness induced by levamisole.
    Golding H; Golding B; Jacobson R; Lomnitzer R; Koornhof HJ; Rabson AR
    Clin Exp Immunol; 1976 Nov; 26(2):295-301. PubMed ID: 791550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunity in Hodgkin's disease.
    Advani SH; D'Silva H; Gothoskar BP; Dinshaw KA; Nair CN; Gopalkrishna R; Talwalkar GV; Desai PB
    Cancer; 1979 Feb; 43(2):492-9. PubMed ID: 421176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effect of levamisole on various indicators of cellular immunity in amyloidosis].
    Khasabov NN; Mukhin NA; Sura VV; Osipova IN; Varshavskiĭ VA
    Ter Arkh; 1978; 50(2):115-9. PubMed ID: 644475
    [No Abstract]   [Full Text] [Related]  

  • 16. [E-RFC (T cells) and Ig-positive cells (B cells) in the peripheral blood of patients with lymphogranulomatosis and possible immunocorrection with levamisole].
    Markova TP; Danilova NV
    Ter Arkh; 1985; 57(7):15-8. PubMed ID: 3876611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary evaluation of immunotherapy in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Karpowicz M; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Małkowska-Zwierz W; Pawelski S
    Arch Immunol Ther Exp (Warsz); 1981; 29(6):739-55. PubMed ID: 7349093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levamisole, an immunostimulant agent].
    Schaus R
    Bull Soc Sci Med Grand Duche Luxemb; 1977 Dec; 114(2):109-11. PubMed ID: 610961
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of BCG or levamisole as an adjunct to chemotherapy or radiotherapy in malignant lymphomas.
    Advani SH; Gangal SG; Gopal R; Nair CN; Dinshaw KA; Desai PB
    Indian J Med Res; 1985 Mar; 81():306-12. PubMed ID: 4018861
    [No Abstract]   [Full Text] [Related]  

  • 20. The influence of splenectomy, radiotherapy and chemotherapy on the immune response in Hodgkin's disease.
    Van Rijswijk RE; Sybesma JP; Kuipers JT; Zegers BJ; Borst-Eilers E
    Neth J Med; 1976; 19(4-5):201-8. PubMed ID: 980188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.